Qualcomm has announced a deal with IT specialist Cerner to extend the capture of vital patient data from devices in the home and send it to healthcare providers monitoring their conditions.
Celgene has stepped up with a deal to buy a $45 million chunk of Mesoblast's stock at a premium price in exchange for a front row seat on the Australian biotech's stem cell pipeline and a preferred spot at the bargaining table if it follows up with a licensing deal.
Eager to expand further into cutting-edge therapy areas, Australia's Mesoblast and U.S.-based Celgene entered into an investment and development deal for cancer and immune-inflammatory related diseases that also covers stem cell product candidates.
India's Mankind Pharmaceuticals intends to take on the nation's giant drugmakers by spending more than $80 million acquiring local pharmas in niche markets, its managing director said in an interview. It also seeks licensing deals with multinationals, he said.
Suven Life Sciences is betting $25 million on U.S. clinical trials for its SUVN-502 as a necessary step to attract other companies to license the drug based on a molecule for treating Alzheimer's disease.
Six years after Catalyst Biosciences inked a $500 million-plus deal to develop Factor VIIa therapies for hemophilia, Pfizer is walking away from the pact it inherited from Wyeth. And now Targacept, which just struck a reverse merger pact to get Catalyst on to the public market, is considering the implications for their tie-up after the biotech's stock took a nasty dive as news of the breakup spread.
CRO giant Parexel International has unveiled three new education programs in partnership with schools around the world, lending its expertise in hopes of training the next generation of clinical researchers.
The operators of a pair of private hospital networks, one in Japan and the other in South Korea, signed a memorandum of understanding to cooperate on research into regenerative medicine, the work ranging from education activities to clinical applications.
PPD and partner Shin Nippon Biomedical Laboratories have hit the ground running with their Japanese joint venture, closing a deal that will see them join forces in the country's growing market for clinical trials.
Australia's Phylogica signed an equity stake licensing agreement with U.K.-based PhoreMost for the use of certain Phylomer libraries solely for phenotypic screening to identify novel targets for diseases such as cancer and develop small molecule drugs.